EVGN on Nasdaq

Evogene Ltd

Logo: Litalmam, CC BY-SA 4.0, via Wikimedia Commons4

Evogene (NASDAQ: EVGN, TASE: EVGN) is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs.3 It was founded in 2002.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 20, 2026.

Overview

$3.9MRevenue, fiscal 20255
-$7.8MNet income, fiscal 20255
2002Founded1

Compare with Cibus, Inc., SenesTech, Inc. or Bioceres Crop Solutions Corp., or pick any stock.

  • TickerEVGN on Nasdaq1
  • Industrybiotechnology1
  • HeadquartersRehovot1
  • Founded inIsrael1
  • Websitewww.evogene.com
  • Legal formlimited company1
  • Listed onNew York Stock Exchange (EVGN), Tel Aviv Stock Exchange (EVGN)1
  • Incorporated inIsrael6
  • Business address13 Gad Feinstein Street, Park Rehovot, Rehovot, L3 76385176
  • Filer categoryNon-accelerated filer6

See how the biggest companies compare on our leaderboards

Evogene (NASDAQ: EVGN, TASE: EVGN) is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-6.3%Gross margin5
-364.2%Operating margin5
-203.1%Net margin5
-30.9%Revenue growth, 20255
-65.4%Return on equity5
-$13.6MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Industry brought in 56% of the revenue Evogene Ltd broke down this way in fiscal 2025.

  1. Industry$2.2M556%down 2% from 2024
  2. Agriculture$1.4M536%down 54% from 2024
  3. Unallocated$311.0K58%down 4% from 2024
Business segments by year
Business segments202320242025
Industry$1.1M$2.2M$2.2M
Agriculture$1.1M$3.0M$1.4M
Unallocated$287.0K$323.0K$311.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue22¢$4.1M
  • Research and development44¢$8.0M
  • Selling, general and admin23¢$4.3M
  • Interest11¢$1.9M
  • Income tax0¢$1.0K

Out of $3.9M in revenue.5 The company lost money this year.

Financial statements

Revenue891011125$3.9M in 2025+121% since 2018
0$2.0M$4.0M$6.0M2018: $1.7M$1.7M20182019: $753.0K$753.0K2019−57%2020: $1.0M$1.0M2020+38%2021: $930.0K$930.0K2021−11%2022: $1.7M$1.7M2022+80%2023: $3.0M$3.0M2023+78%2024: $5.6M$5.6M2024+87%2025: $3.9M$3.9M2025−31%
Gross profit891011125-$241.0K in 2025
-$1.0M0$1.0M$2.0M$3.0M$4.0M2018: $295.0K$295.0K20182019: $419.0K$419.0K2019+42%2020: $466.0K$466.0K2020+11%2021: $163.0K$163.0K2021−65%2022: $766.0K$766.0K2022+370%2023: $1.5M$1.5M2023+95%2024: $3.2M$3.2M2024+114%2025: -$241.0K-$241.0K2025
Operating income891011125-$14.0M in 2025−30% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M02018: -$20.0M-$20.0M20182019: -$21.2M-$21.2M2019+6%2020: -$24.8M-$24.8M2020+17%2021: -$31.0M-$31.0M2021+25%2022: -$26.9M-$26.9M2022−13%2023: -$22.2M-$22.2M2023−17%2024: -$18.8M-$18.8M2024−15%2025: -$14.0M-$14.0M2025−25%
Net income891011125-$7.8M in 2025−62% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M02018: -$20.8M-$20.8M20182019: -$19.1M-$19.1M2019−8%2020: -$26.2M-$26.2M2020+37%2021: -$30.4M-$30.4M2021+16%2022: -$29.8M-$29.8M2022−2%2023: -$26.0M-$26.0M2023−13%2024: -$18.1M-$18.1M2024−30%2025: -$7.8M-$7.8M2025−57%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Revenues$3.9M$5.6M$3.0M
Inventory impairment$2.2M$0$0
Other Cost Of Revenues$1.9M$2.4M$1.5M
Total cost of revenues$4.1M$2.4M$1.5M
Gross profit (loss)-$241.0K$3.2M$1.5M
Research and development, net$8.0M$12.5M$16.2M
Sales and marketing$1.5M$2.0M$2.2M
General and administrative$4.3M$7.0M$5.4M
Other expenses$37.0K$514.0K$0
Total operating expenses, net$13.8M$22.0M$23.7M
Operating income (loss)-$14.0M-$18.8M-$22.2M
Financing income$2.5M$7.4M$1.2M
Financing expenses-$1.9M-$3.4M-$928.0K
Financing income (expenses), net$575.0K$4.0M$285.0K
Share of loss of an associate$39.0K$39.0K$0
Income (loss) before taxes on income-$13.5M-$14.8M-$21.9M
Taxes on income$1.0K$9.0K$19.0K
Profit (loss) from continuing operations-$13.5M-$14.8M-$22.0M
Income (loss) from discontinued operations, net$5.7M-$3.2M-$4.0M
Income (loss) after taxes on income-$7.8M-$18.1M-$26.0M
Equity holders of the Company-$8.5M-$16.5M-$23.9M
Non-controlling interests$658.0K-$1.6M-$2.1M
Basicloss per share from continuing operations, attributable to equity holders of the Company-$1.70-$2.47-$4.56
Diluted loss per share from continuing operations, attributable to equity holders of the Company-$1.70-$2.47-$4.56
Basic earnings (loss) per share from discontinued operations$0.62-$0.43-$0.64
Diluted earnings (loss) per share from discontinued operations$0.62-$0.43-$0.64
Basic loss per share, attributable to equity holders of the Company$1.08-$2.90-$5.20
Diluted loss per share, attributable to equity holders of the Company$1.08-$2.90-$5.20
Weighted average number of shares used in computing basic gain (loss) per share7.9M shares5.7M shares4.6M shares
Weighted average number of shares used in computing diluted gain (loss) per share7.9M shares5.7M shares4.6M shares

Compare Evogene Ltd with another company

Corporate structure

Evogene Ltd sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Evogene Ltd

  • L.I.A. Pure Capital Ltd Filed SCHEDULE 13D/A on Evogene Ltd, latest Oct 6, 2026 (8 filings since Jul 10, 2026)
  • Leon Recanati Filed SCHEDULE 13D/A on Evogene Ltd, latest Sep 11, 2026 (3 filings since Aug 11, 2026)
  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Evogene Ltd, latest Aug 14, 2026 (2 filings since May 15, 2026)
  • SILVERARC CAPITAL MANAGEMENT, LLC Filed SC 13G/A on Evogene Ltd, latest Oct 15, 2024 (2 filings since Feb 14, 2024)
  • Macquarie Group Filed SC 13G/A on Evogene Ltd, latest Feb 11, 2022
  • ARK Investment Management LLC Filed SC 13G/A on Evogene Ltd, latest Feb 9, 2022

Built from subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Evogene Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$812.0K5 Dec 31, 2025$1.8M5 Dec 31, 2024−55.0%
Operating-lease assets (leased space)$1.8M5 Dec 31, 2025$2.4M5 Dec 31, 2024−25.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$13.0M5 Dec 31, 2025$15.3M5 Dec 31, 2024−15.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$05 Dec 31, 2025$12.2M5 Dec 31, 2024−100.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$210.0K5 Dec 31, 2025$1.8M5 Dec 31, 2024−88.5%

Leadership

Who has led Evogene Ltd, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ofer Haviv2026–now

President

  1. Ofer Haviv2026–now

Chief financial officer

  1. Yaron Eldad2026–now
20052010201520202025
Board members and other officers (7)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Vice President of Business DevelopmentEyal Ronen named Sep 4, 202422
  • Chief Technology OfficerMark Kapel named Sep 4, 202422
  • Vice President Corporate DevelopmentSassi Masliah named Sep 4, 202422
  • DirectorDan Falk named Sep 4, 2024 to Feb 19, 202623
  • DirectorLeon Yehuda Recanati named Feb 19, 202623
  • DirectorLeon Y. Recanati named Sep 4, 202422
  • DirectorOded Y. Shoseyov named Sep 4, 202422

Products and brands

Evogene has developed computational biology platforms leveraging big data and artificial intelligence (AI), including machine learning algorithms.

In June 2007, Haaretz reported that Evogene announced a collaboration with SunGene of Germany to develop plant biotechnology-engineering techniques. The project was supported by the Israel-Germany BioDisc program, the Israeli Ministry of Science and Technology, and Germany’s Federal Ministry of Education and Research. The collaboration aimed to develop methods for improving gene implantation in crops.

In September 2008, Evogene formed a joint venture with the Leviev Group and Ormat Group to develop and commercialize castor plants for biodiesel production in Namibia.

In June 2009, Evogene signed a licensing agreement with Syngenta to develop soybean strains resistant to nematode pests. The agreement included research funding, milestone payments, and potential royalties, and was part of Evogene’s ongoing collaborations with firms such as Monsanto and Bayer.

Read the full text

In March 2015, The Times of Israel reported that Evogene was using genomic technologies, including its PointHit platform, to analyze molecules in weeds and identify plant macromolecules for herbicide development. The article also noted that Monsanto was a major investor in the company.

In July 2018, Evogene partnered with Brazil’s Instituto Mato-grossense do Algodão (IMAmt) to identify genes for insect-resistant cotton targeting the boll weevil and fall armyworm.

In June 2020, The Jerusalem Post reported that Evogene was among the companies selected to participate in a NIS 36 million consortium funded by the Israel Innovation Authority to develop genome editing tools using CRISPR and artificial intelligence.

Evogene states that its computational platform is designed to improve the efficiency of life-science product development by leveraging big data and AI. The company reports that its approach aims to reduce development time and cost while identifying potential products with lower toxicity. Its reported partners include BASF (OTCQX:BASFY), Bayer (OTCPK:BAYZF), Corteva (CTVA), ICL Group Ltd. (ICL) as well as academic and medical institutions.

Subsidiaries

In October 2014, Evogene’s subsidiary Evofuel signed an agreement with the Brazilian Agricultural Research Corporation (Embrapa) to develop castor cultivation technologies for biofuel production.

In August 2022, The Jerusalem Post reported that Evogene’s subsidiary Biomica began a Phase I clinical trial for its microbiome-based drug candidate BMC128 at Rambam Health Care Campus. The drug, developed using Evogene’s MicroBoost AI platform, is designed to improve cancer patients’ response to immunotherapy. In December 2022, Biomica secured a $20 million funding agreement led by Shanghai Healthcare Capital to advance its microbiome-based therapeutics.

In June 2023, Casterra, a subsidiary of Evogene, signed a $9.1 million agreement with an international oil and gas company to supply castor seeds for biofuel production in Africa. According to The Times of Israel, the seeds were developed using genomic methods based on Evogene’s computational platform to increase oil yield.

From Wikipedia’s article on Evogene, shared under CC BY-SA 4.0.7

Subsidiaries and ownership

Subsidiaries

From Wikidata.1

Timeline

  1. Mar 18, 2026New chief executive Ofer Haviv becomes CEO14
  2. 2002Founded Founded in Israel1

Calendar

Coming up

  1. Nov 19, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.31) a share, on Nov 20, 2025.24

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

203 filings to the SEC since October 2021: 5 annual reports, 17 insider forms, 17 large holders, 2 private raises, 162 other. The latest 20:

  1. Oct 6, 2026SCHEDULE 13D/A EDGAR
  2. Oct 6, 20266-K EDGAR
  3. Sep 30, 20264 EDGAR
  4. Sep 30, 20264 EDGAR
  5. Sep 30, 20264 EDGAR
  6. Sep 30, 20264 EDGAR
  7. Sep 30, 20266-K EDGAR
  8. Sep 29, 2026EFFECT EDGAR
  9. Sep 28, 20266-K EDGAR
  10. Sep 28, 2026POS AM EDGAR
  11. Sep 15, 20266-K EDGAR
  12. Sep 11, 2026SCHEDULE 13D/A EDGAR
  13. Sep 11, 2026SCHEDULE 13D/A EDGAR
  14. Sep 4, 20266-K EDGAR
  15. Aug 28, 2026SCHEDULE 13D/A EDGAR
  16. Aug 27, 20266-K EDGAR
  17. Aug 26, 20264 EDGAR
  18. Aug 18, 20266-K EDGAR
  19. Aug 14, 2026SCHEDULE 13G/A EDGAR
  20. Aug 13, 2026SCHEDULE 13D/A EDGAR

The 203 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 11, 2026RECANATI LEONDirectorBuy460,000$0.64$294.4KForm 4
Aug 4, 2026RECANATI LEONDirectorBuy800,000$0.50$400.0KForm 4
Jun 4, 2026Tarcic GabiChief Development OfficerBuy1,129$0.60$677Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 11, 2026Raised $3.4 million in a private offering of securities Form D: 1 investor so far Form D
  2. Aug 23, 2024Filed a private offering of securities Form D: $12 million offered in all Form D

SEC filer profile

How Evogene Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREvogene Ltd.2
  • CIK0001574565
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company31
  • Incorporated inIsrael31
  • Fiscal year endsDecember 312
  • Industry code (SIC)2870 Agricultural Chemicals2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address13 Gad Feinstein Street, Park Rehovot, Rehovot, L3 76385172
  • Phone972893119002
  • Shares outstanding8,718,193 shares as of Dec 31, 202531
  • AuditorKOST FORER GABBAY & KASIERER, Tel-Aviv, Israel PCAOB ID 1281; no auditor attestation of internal control over financial reporting31
  • On EDGAR sinceApr 26, 20132
  • Filings460 in all: 6-K (270), SC 13G/A (36), SC 13G (21), 20-F (13), UPLOAD (13), 3 (10), EFFECT (10), 424B5 (9)2
    All 32 form types

    CORRESP (9), SCHEDULE 13D/A (9), 4 (7), 424B3 (7), F-1/A (6), S-8 (6), F-3 (4), POS AM (4), 6-K/A (3), DRS/A (3), DRSLTR (3), 8-A12B (2), D (2), F-1 (2), SCHEDULE 13D (2), 20-F/A (1), 25 (1), 424B4 (1), CERTNAS (1), CERTNYS (1), CT ORDER (1), DRS (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (20-F) Mar 26, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary shares, par value NIS 0.2 per shareEVGNNasdaq

From the cover page of the 20-F filed Mar 26, 2026 (Section 12(b) of the Exchange Act).31

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31